AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open-Label...

Area of Science:

• Neuroscience
• Pharmacology
• Rare Diseases

Background:

• Progressive supranuclear palsy (PSP) is a rare, fatal neurodegenerative tauopathy with limited treatment options.
• Current management focuses on symptomatic relief, highlighting the need for disease-modifying therapies.

Purpose of the Study:

• To assess the safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of AZP2006 in patients with PSP.
• AZP2006 is an oral pleiotropic drug designed to modulate progranulin levels.

Main Methods:

• A 12-week, randomized, double-blind, placebo-controlled trial involving 36 patients with probable or possible PSP.
• Participants received AZP2006 (60 mg or 80/50 mg) or placebo, with assessments of safety, pharmacokinetics, biomarkers, and clinical outcomes.
• An open-label extension (OLE) followed for 6 months in 15 patients.

Main Results:

• AZP2006 was well-tolerated and safe, with no serious adverse events related to treatment.
• Pharmacokinetic analysis revealed rapid absorption and a long half-life, with steady-state achieved by week 4-6.
• Biomarker data indicated blood-brain barrier penetration and target engagement, with stabilized progranulin levels. Efficacy trends favored AZP2006, showing slower disease progression. OLE confirmed slowed progression without safety concerns.

Conclusions:

• AZP2006 demonstrated favorable safety, tolerability, and preliminary biomarker and clinical outcome trends in PSP patients.
• These findings support further investigation into AZP2006's potential for meaningful clinical benefit in progressive supranuclear palsy.